Adherex Technologies (FENC)
(Real Time Quote from BATS)
$6.54 USD
-0.07 (-1.06%)
Updated Jul 26, 2024 03:44 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FENC 6.54 -0.07(-1.06%)
Will FENC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FENC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FENC
Implied Volatility Surging for Fennec (FENC) Stock Options
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
FENC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for FENC
Fennec Announces Results of Annual Meeting
Fennec Pharmaceuticals Directors Elected Confidently
Fennec Pharmaceuticals: A Strong Buy on Pedmark’s Promising Market Prospects and Growth Initiatives
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today